Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Eikon Therapeutics, Inc. is a late-stage clinical biopharmaceutical company pioneering advanced drug discovery through visualization of protein motion in living cells. Founded in 2019 and headquartered in Millbrae, California, it employs 384 people and focuses on developing therapies primarily for cancer treatment using innovative imaging techniques. The company integrates cutting-edge technology to observe dynamic protein behaviors, aiming to revolutionize how drugs are identified and optimized for oncology indications. Key leadership includes CEO Roger Perlmutter, co-founders Xavier Darzacq, Robert Tjian, and Eric Betzig, alongside experts like Chief Scientific Officer Dan Anderson and Chief Medical Officer Roy Baynes. Supported by prominent investors such as T. Rowe Price, Lux Capital, General Catalyst, and Foresite Capital, Eikon Therapeutics has raised substantial funding through multiple rounds, including a $351 million Series B in 2025. Operating in the biological products sector, it plays a significant role in advancing precision medicine for challenging diseases.
$10.33
$0.09 (-0.86%)
EOD Aug 13, 2026
Negative free cash flow of -$235M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (FY)
$0.00
Net Income (FY)
-$324M
▼ -33.0% YoY
Op. Margin
—
ROIC
-116.48%
▲ +59.2pp YoY
Cash Flow & Balance Sheet
FCF (FY)
-$235M
▼ -7.1% YoY
Op. Cash Flow (FY)
-$189M
▼ -36.0% YoY
Net Debt
-$79M
Net Cash Position
Cash & Equiv.
$336M
Continue Research
Eikon Therapeutics (EIKN)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Eikon Therapeutics scores 13/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Eikon Therapeutics scores 13 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -116.5% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh EIKN's valuation and scores 13/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.